Q-omics provides the consensus-scored KLHL13 profile across patient tissues and cancer cell-line models. KLHL13 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KLHL13 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, KLHL13 RNA expression shows 18,640 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where KLHL13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLHL13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLHL13 survival associations across molecular data types. KLHL13 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLHL13 RNA expression–survival associations across cancer types. High KLHL13 expression shows unfavorable associations in KIRP, HNSC and STAD, but favorable associations in KIRC, LUSC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KLHL13 RNA expression.
This table summarizes KLHL13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KLHL13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLHL13 shows lower tumor expression in KIRC, KICH, BLCA and COAD and higher tumor expression in HNSC and LUSC. The KIRC box plot shows higher KLHL13 RNA expression in normal versus tumor tissue (log2 FC = −1.805, t-test p < 0.001).
This table shows molecular features associated with KLHL13 in patient tissues and cancer cell lines. In patient samples, KLHL13 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KLHL13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
